Differential Killing of Mismatch Repair-Deficient and -Proficient Cells: Towards the Therapy of Tumors with Microsatellite Instability

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8113-8117

  Cejka, Petr ^a   Marra, Giancarlo ^a   Hemmerle, Christine ^a   Cannavó, Elda ^a   Storchova, Zuzana ^a,b   Jiricny, Josef ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GANCICLOVIR; HYBRID PROTEIN; THYMIDINE KINASE BLASTICIDIN DEAMINASE FUSION PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; EMBRYO; FRAMESHIFT MUTATION; FUSION GENE; GENE CONSTRUCT; GENE MUTATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHENOTYPE; PRIORITY JOURNAL;

AMINOHYDROLASES; ASPERGILLUS; BASE PAIR MISMATCH; CARRIER PROTEINS; CELL LINE; DNA REPAIR; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HERPES SIMPLEX; HUMANS; MICROSATELLITE REPEATS; MUTAGENESIS; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; THYMIDINE KINASE; TRANSFECTION;

EID: 0346365378     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kunkel, T. A. Nucleotide repeats. Slippery DNA and diseases. Nature (Lond.), 365: 207-208, 1993.
2. Veigl, M. L., Kasturi, L., Olechnowicz, J., Ma, A., Lutterbaugh, J. D., Periyasamy, S., Li, G. M., Drummond, J., Modrich, P. L., Sedwick, W. D., and Markowitz, S. D. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. USA, 95: 8698-8702, 1998.
3. Herman, J., Umar, A., Polyak, K., Graff, J., Ahuja, N., Issa, J., Markowitz, S., Willson, J., Hamilton, S., Kinzler, K., Kane, M., Kolodner, R., Vogelstein, B., Kunkel, T. A., and Baylin, S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.
4. Peltomaki, P. DNA mismatch repair and cancer. Mutat. Res., 488: 77-85, 2001.
5. Anthoney, D. A., Mcllwrath, A. J., Gallagher, W. M., Edlin, A. R., and Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56: 1374-1381, 1996.
6. Karran, P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis (Lond.), 22: 1931-1937, 2001.
7. 2-M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J., 22: 2245-2254, 2003.
8. Aquilina, G., Ceccotti, S., Martinelli, S., Hampson, R., and Bignami, M. N-(2-chloroethyl)-N'-Cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer. Res., 58: 135-141, 1998.
9. Hanford, M. G., Rushton, B. C., Gowen, L. C., and Farber, R. A. Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair. Oncogene, 16: 2389-2393, 1998.
10. Gasche, C., Chang, C. L., Natarajan, L., Goel, A., Rhees, J., Young, D. J., Arnold, C. N., and Boland, C. R. Identification of frame-shift intermediate mutant cells. Proc. Natl. Acad. Sci. USA, 100: 1914-1919, 2003.
11. Boyer, J. C., Yamada, N. A., Roques, C. N., Hatch, S. B., Riess, K., and Farber, R. A. Sequence-dependent instability of mononucleotide microsatellites in cultured mismatch repair proficient and deficient mammalian cells. Hum. Mol. Genet., 11: 707-713, 2002.
12. Kahn, S. M., Klein, M. G., Jiang, W., Xing, W. Q., Xu, D. B., Perucho, M., and Weinstein, I. B. Design of a selectable reporter for the detection of mutations in mammalian simple repeat sequences. Carcinogenesis (Lond.), 16: 1223-1228, 1995.
13. Karreman, C. New positive/negative selectable markers for mammalian cells on the basis of Blasticidin deaminase-thymidine kinase fusions. Nucleic Acids Res., 26: 2508-2510, 1998.
14. Bellacosa, A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ., 8: 1076-1092, 2001.
15. Bhattacharyya, N. P., Skandalis, A., Ganesh, A., Groden, J., and Meuth, M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 91: 6319-6323, 1994.
16. Boyer, J. C., and Farber, R. A. Mutation rate of a microsatellite sequence in normal human fibroblasts. Cancer Res., 58: 3946-3949, 1998.
17. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
18. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
19. Hall, S. J., Canfield, S. E., Yan, Y., Hassen, W., Selleck, W. A., and Chen, S. H. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad, HSV-tk and Ad. mIL-12 gene therapies in experimental prostate cancer. Gene Ther., 9: 511-517, 2002.